XRAY

• GAAP diluted EPS was $0.18, compared to a loss of $0.22 in Q2 2025; adjusted EPS was $0.52, flat year-over-year.
• Adjusted EBITDA was $190 million, down 3.3% from $197 million in Q2 2025; adjusted EBITDA margin was 21.3%.
• The company repurchased 1.3 million shares for approximately $12 million during the quarter and had $239 million in cash as of June 30, 2026.
• Dentsply Sirona reiterated its 2026 outlook for net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.

9.01 Financial Statements and Exhibits

• John C. Fortson, age 58, will become Executive Vice President & Chief Financial Officer of DENTSPLY SIRONA Inc., effective July 20, 2026.
• His compensation includes an annual base salary of $780,000, a target annual bonus of 85% of base salary, and a $500,000 sign-on cash payment payable in February 2027.
• He will receive a sign-on equity award with a target grant date fair value of $700,000 (60% premium stock options, 40% restricted stock units) with three-year ratable vesting.
• Beginning in 2027, he will be eligible for an annual equity award with a target grant date fair value of $2,500,000.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Shareholders ratified Deloitte & Touche LLP as independent auditor for 2026 with 182,033,381 votes for.
• The non-binding advisory vote on 2025 executive compensation passed with 158,496,058 votes for.
• Amendment No. 2 to the 2024 Omnibus Incentive Plan, increasing shares by 15,000,000, was approved with 139,933,388 votes for.
• The report was filed under Item 5.07 to disclose the voting results of the annual meeting.

5.07 Submission of Matters to a Vote of Security Holders

• GAAP gross margin was 48.5%, down from 53.0% in Q1 2025; GAAP net loss attributable to Dentsply Sirona was $10 million, or ($0.05) per diluted share.
• Adjusted gross margin was 50.7%, adjusted EBITDA margin was 14.7%, and adjusted EPS was $0.27.
• Operating cash flow was $40 million in Q1 2026, up from $7 million in Q1 2025; free cash flow was ($12) million, unchanged year-over-year.
• The company reiterated its 2026 outlook for net sales of $3.5 billion to $3.6 billion and adjusted EPS of $1.40 to $1.50.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• Q4 2025 reported net loss was $146 million, with diluted loss per share of $0.74, including $144 million in goodwill and intangible impairments.
• Full year 2025 net sales were $3,680 million, down 3.0% year-over-year; adjusted EPS was $1.60.
• The company provided FY 2026 outlook of net sales between $3.5 billion and $3.6 billion and adjusted EPS between $1.40 and $1.50.
• The company eliminated its dividend and approved a restructuring plan expected to generate approximately $120 million in annualized cost savings.

2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits

• James D. Forbes and Brian P. McKeon were appointed to the Board, effective February 27, 2026, until the 2026 annual meeting.
• Forbes will serve on the Compensation & Human Capital Committee; McKeon on the Audit and Finance and Science and Technology Committees.
• Willie A. Deese notified the Board of his intent not to seek reelection at the 2026 annual meeting, not due to any disagreement.
• Forbes and McKeon will participate in the same compensation plans as other non-employee directors.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• Dentsply Sirona and Patterson Dental announced the renewal of their U.S. dental technology distribution agreement on January 14, 2026.
• Patterson Dental customers will continue to have access to Dentsply Sirona's full portfolio, including CEREC, Primescan, Axeos, and Orthophos systems.
• The companies aim to accelerate growth and expand access to integrated dental technology solutions.
• The press release was furnished as Exhibit 99.1 to the Form 8-K under Item 7.01 Regulation FD Disclosure.

7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits

• The Board increased its size from 10 to 11 directors and appointed Donald J. Zurbay, effective January 10, 2026.
• He has no family relationships or material interests requiring disclosure under Item 404(a) of Regulation S-K.
• He will participate in the same compensation plans as other non-employee directors, as described in the April 9, 2025 proxy statement.
• The Board also formed a special four-member Growth and Value Creation Committee, co-chaired by Chairman Gregory T. Lucier and CEO Daniel T. Scavilla.

5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits